Table 2.
Complications in partial splenic artery embolization
| Ref. | Year | Country | Study type | Complication: Frequency of post embolization syndrome | Complication: Mean length of post embolization syndrome-Days | Major complications: Total number | Persistant thrombocytopenia | Splenomegaly | Pleural effusion/ascites | Variceal bleeding | Portal vein thrombosis | Bacterial peritonitis | Splenic abscess | PSE-related death | Repeat embolization required |
| Kim et al[11] | 2012 | South Korea | Case series report | 100.00% | Not provided | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Elmonem et al[12] | 2010 | Egypt | Case series report | 91.30% | Not provided | 34.80% | 4.30% | 4.30% | 8.70% | 0.00% | 4.30% | 4.30% | 4.30% | 4.30% | 4.30% |
| Zhu et al[14] | 2009 | China | Nonrandomized prospective trial | Total 85.5% Group A: 100% Group B: 91.2% Group C: 62.5% | Group A: 13 Group B: 7 Group C: 3 | Total 14.5% Group A: 50% Group B: 8.8% Group C: 0% | Total 0% Group A: 0% Group B: 0% Group C: 0% | Total 0% Group A: 0% Group B: 0% Group C: 0% | Total 4.8% Group A: 16.6% Group B: 2.9% Group C: 0% | Total 1.6% Group A: 8.3% Group B: 0% Group C: 0% | Total 1.6% Group A: 8.3% Group B: 0% Group C: 0% | Total 1.6% Group A: 8.3% Group B: 2.9% Group C: 0% | Total 1.6% Group A: 8.3% Group B: 0% Group C: 0% | Total 1.6% Group A: 8.3% Group B: 0% Group C: 0% | Total 0% Group A: 0% Group B: 0% Group C: 0% |
| Amin et al[9] | 2009 | Egypt | Randomized control trial | Not provided | PSE: 2.1 (0.4) SPL: 4.3 (1.1) | PSE: 25% SPL: 25% | PSE: 0% SPL: 0% | PSE: 0% SPL: 0% | PSE: 10% SPL: 10% | PSE: 0% SPL: 0% | PSE: 5% SPL: 15% | PSE: 0% SPL: 0% | PSE: 5% SPL: 0% | PSE: 5% SPL: 0% | PSE: 0% SPL: 0% |
| Zhu et al[16] | 2008 | China | Randomized control trial | GF: 90.6% PVA: 100% | GF: 6.4 (3.6) PVA: 7.6 (2.8) | GF: 25.0% PVA: 21.4% | GF: 0% PVA: 0% | GF: 0% PVA: 0% | GF: 9.4% PVA: 10.7% | GF: 3.1% PVA: 3.6% | GF: 3.1% PVA: 7.1% | GF: 6.3% PVA: 0% | GF: 3.1% PVA: 0% | GF: 3.1% PVA: 0% | GF: 0% PVA: 0% |
| Hayashi et al[17] | 2007 | Japan | Nonrandomized prospective trial | 100.00% | Not provided | 11.90% | 0.00% | 0.00% | 9.50% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Lee et al[15] | 2007 | China | Nonrandomized prospective trial | 100.00% | Not provided | 10.00% | 0.00% | 0.00% | 10.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| N'Kontchou et al[13] | 2005 | France | Retrospective review | 78.10% | 14 | 28.10% | 3.10% | 0.00% | 6.30% | 0.00% | 6.30% | 0.00% | 6.30% | 6.3%1 | 3.10% |
1
Both deaths in the trial were in patients with > 70% splenic embolization. PSE: Partial splenic artery embolization; SPL: Splenectomy; GF: Gel foam; PVA: Polyvinyl alcohol.